Nine-fold risk of narcolepsy in young people with GSK's Pandemrix, says Finnish govt study
This article was originally published in Scrip
GlaxoSmithKline does not have to worry about any possible litigation over whether its fast-approved pandemic H1N1 vaccine, Pandemrix, is linked to narcolepsy thanks to immunity clauses in contracts with governments who bought the vaccine for a pandemic that started in June 2009 and ended in August 2010. But governments do have to worry.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.